AP
DNTH icon

Antipodes Partners’s Dianthus Therapeutics DNTH Stock Holding History

Antipodes Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9K Buy
379
+15
+4% +$1.31K ﹤0.01% 119
2026
Q1 		$30.5K Sell
364
-95
-21% -$5.5K ﹤0.01% 114
2025
Q4 		$18.9K Buy
+459
New +$17.8K ﹤0.01% 124

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Antipodes Partners's DNTH Position: Q2 2026 in Review

Antipodes Partners increased its Dianthus Therapeutics (DNTH) stake by 4.1% in Q2 2026, buying an estimated $1.31K and bringing the position to 379 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #119.

Antipodes Partners first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Antipodes Partners held 379 shares of Dianthus Therapeutics worth $36.9K as of Q2 2026.
  • Antipodes Partners bought 15 Dianthus Therapeutics shares in Q2 2026, an estimated $1.31K.
  • Dianthus Therapeutics made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #119 holding.
  • Antipodes Partners first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.